Research & Development News

Thalassaemia patients to get oral treatment.

New acquisition involves revolutionary vascular technology.

Drug development to be aided by new biosensor

New grant to encourage plasma transfer research

Preliminary Data Analysis Supports Excellent Safety and Side Effect Profile of Somatoprim

Ethris GmbH and Shire today announce the initiation of a research based alliance focused on the development and commercialization of novel RNA-based therapeutics.

Clinigen Group is managing a patient program for a drug used to treat overexposure to chemotherapy.

FDA approval has been granted to new generic ADHD extended-release tablets from Mallinckrodt.

Evotec has acquired CCS and will integrate its capabilities into existing operations at its Hamburg site.

A clinical trial is to establish whether there is a genetic link to severe asthma.

Cellular Dynamics International, Inc. (CDI) entered a Center of Excellence agreement with AstraZeneca to accelerate drug discovery efforts using human induced pluripotent stem cell (iPSC) lines and tissue cells.

Asklep has joined the Medidata Solutions Partner Programme to increase the quality and efficiency of clinical trials.

A newly found understanding of receptor signaling may have revealed a better way to design drugs.

An international research have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.

A novel approach to identifying potential anticancer drug combinations revealed that pairing cholesterol-reducing drugs called statins with cyclin-dependent kinase inhibitors might provide an effective approach to treating intractable melanomas driven ...

A new stem cell-derived system for screening experimental drugs for cardiotoxicity could identify dangerous side effects early in the development process.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and GE Healthcare today announced a clinical study collaboration.

Researchers at Mayo Clinic's campus in Florida have identified an enzyme specifically linked to aggressive prostate cancer.

Phenex will receive an upfront payment and is eligible to receive development-related milestones.

A review has identified industry sponsorship as an important source of bias in clinical trial reports.

PerkinElmer has added a range of new assay kits to its product portfolio.

PDC Biotech GmbH (PDC) today announced that it has successfully completed a phase I clinical trial for its lead compound for the treatment of preterm labour .

AOP Orphan announces results from phase II trial in PV at ASH Annual Meeting in Atlanta, U.S.A. Promising efficacy and safety data support further development of AOP2014/P1101 AOP2014/P1101 received Orphan Drug designation in 2011 AOP Orphan is init...

A study suggests three or fewer trial sites may be best for phase-I clinical trials.

The research collaboration between Protagonist and Ironwood is being expanded after making 'remarkable' progress.

Sol-Gel Technologies Ltd. announced today positive results for a Phase II trial in the U.S. targeting mild-to-severe rosacea using a benzoyl peroxide drug product developed by Sol-Gel.

Innovative nanofleece technology provides high flow rates and total throughput performance in combination with excellent clarification capabilities New series concludes the launch of SSB´s Sartoguard range of prefilters

GSK, Johnson & Johnson and Sanofi are doing the most to improve access to medicines in developing countries.

A novel technology could enable scientists to develop thermostable influenza vaccines.

ACM Global Central Laboratory's new facility in York, England, doubles its laboratory and office space.

Discovery of a new drug with high potential to treat Ewing sarcoma, an often deadly cancer of children and young adults.

Aptiv Solutions has opened a new office in Durham, NC in a business park convenient to Raleigh, Durham, Chapel Hill, Cary and Research Triangle Park.

Capsugel has opened its new quality control lab in Greenwood, SC, doubling its lab capacity and investing more than $3 million.

Bend Research, PATH, and Fraunhofer USA Center for Molecular Biotechnology (FhCMB) have developed a new technology for thermostable vaccine production.

Treating Parkinson's disease patients with the experimental drug GM1 ganglioside improved symptoms and slowed their progression during a two and a half-year trial.

Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has added a project under its ongoing research services agreement with Janssen Research & Development.

GBI Research is predicting strong growth in the global cell culture market thanks to increasing demand for biologics and stem cell therapies

Industry representatives and policymakers have met to discuss the future of life sciences research and development in the UK.

Sihuan Pharmaceutical and NeuroVive have announced a collaborative agreement that should help to bring two new cardio-cerebral vascular drugs to market.

A new partnership between Affymetrix and the CPGR in South Africa could ultimately lead to new personalised therapies.

TG Therapeutics and Ildong Pharmaceutical Co have inked a licensing agreement for the development and commercialisation of ublituximab

A report has shed light on pharmaceutical companies' increasing use of adaptive trials.

Shire plc (LSE: SHP, NASDAQ: SHPG) and Boston Children's Hospital today announced a three-year, broad research collaboration in rare diseases.

The discovery of the molecular pathway that drives the changes seen in the brains of Alzheimer's patients is reported today, revealing new targets for drug discovery that could be exploited to combat the disease.

A key gene that determines resistance to a range of cancer drugs has been reported in a study published by Cell Press November 21st in the journal Cell.

Targeted cancer therapy has been transforming the care of patients with non-small-cell lung cancer (NSCLC).

A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment.

Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, introduced their new Universal Phase Separators, a flexible alternative to the traditional glass funnel separation of immiscible...

An international research team reports that they have identified a second gene variant that confers a high risk of acquiring the more common, late-onset form of Alzheimer’s disease.

Fujifilm Diosynth Biotechnologies has added another licensed product to its list of commercial biopharmaceutical products.

Colby and MannKind have revealed details of a new licensing agreement between the two companies.

Quintiles' latest study could pave the way for more direct-to-patient studies using patient-reported outcomes combined with medical record data.

For many people with high cholesterol, statins serve as the first line of treatment.

Scientists in the United States have tested all possible pairings of the 100 cancer drugs approved for use in patients in order to discover whether there are any combinations not tried previously that are effective in certain cancers.

Resveratrol, a compound found commonly in grape skins and red wine, has been shown to have several beneficial effects on human health, including cardiovascular health and stroke prevention.

Ensemble will use its innovative drug discovery platforms to discover and advance drug candidates against Boehringer Ingelheim's drug targets

Portola, BMS and Pfizer aim to find out whether PRT4445 is a safe and effective antidote to Eliquis and other Factor Xa inhibitors.

Airgas and Biologics Modular are partnering up to provide a flexible, cost-effective solution to companies and manufacturers that need to expand their life science assets.

The potential to replenish populations of cells destroyed by disease was seen by many as the next medical revolution.

Scientists have established that a drug recently approved by the U.S. Food and Drug Administration to treat a rare form of cystic fibrosis.

A study shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.

Cutting Edge Information's latest report sheds light on pharmaceutical companies' expenditure on MSL teams.

Idera has published encouraging results from pre-clinical studies involving TLR 7, 8 and 9.

Phase 1b trials are to get underway to test the efficacy of TRU-016 in treating CLL along with rituximab.

Inhibitors may have utility in autoimmune disease treatment

Demand is growing for the Xoft intraoperative radiation therapy system from iCAD.

ImmunoGen believes its new TAP cancer drug has large potential in the treatment of early stage breast and gastric cancers.

US oncologists are taking a cautious approach to prescribing biosimilar versions of monoclonal antibodies.

Bone marrow cancer drug posts promising results in clinical trials.

The world's first fully integrated, commercially available DNA sequencer will be debuted at the Association of Molecular Pathology conference.

A report has explored the growing trend for medical science liaison teams to support investigator-initiated trials.

Pharmaron will provide drug discovery services to pharmaceutical giant AstraZeneca.

GlaxoSmithKline will allow researchers to access detailed clinical trial data upon request.

Ankylosing spondylitis represents a significantly under-served market, a Frost & Sullivan report says.

Highlights Formulation Knowledge Gap for Challenging Compounds and Outsourcing Priorities

A new production facility is being opened by UCB in Belgium to speed up the process of manufacturing cell cultures for clinical trials.

Growing contract research and development services helped Corgenix post record revenues for the year ended June 30th.

ARIAD Pharmaceuticals has published 'compelling' proof-of-concept data for its new tyrosine-kinase inhibitor AP26113.

Cabozantinib is as effective across four key metrics at doses of 40mg a day as it is at doses of 100mg, according to a new study.

A new assay developed by Promega Corporation is capable of improving cytotoxicity reports from cell cultures gathered within 72 hours.

Doctors tend to be biased against industry-funded clinical trials, a study has found.

Critical Outcome Technologies Inc.announced today new data that broadens the mechanism of action (MOA) of the Company's lead oncology asset, COTI-2, beyond AKT inhibition.

Critical Outcome Technologies Inc. announced today that it has initiated the final series of toxicity experiments in two animal species for its lead oncology asset, COTI-2.

The National Institutes of Health’s National Human Genome Research Institute (NHGRI) is restructuring its extramural research program and making other organizational changes to accelerate the application of genomics to medicine.

For the first time, scientists have watched proteins interact with long single-stranded DNA molecules in real time.The new method should yield insights into DNA replication and repair, the researchers say.

Carbohydrates in molecular biology are like dark matter in the universe, according to sialic acid expert Ajit P. Varki of the University of California, San Diego—poorly studied yet crucial to a full understanding of how things actually work.

New data for Lucentis (ranibizumab), the only anti-VEGF therapy licensed across three ocular indications, show that individualized treatment with Lucentis provides sustained improvement in vision with a low number of injections.

Researchers at Emory University have found that a medication that inhibits inflammation may offer new hope for people with difficult-to-treat depression.

Lilly Diabetes announced the release of a new mobile application designed for caregivers and healthcare providers who support people with type 1 diabetes.

Boehringer Ingelheim has announced that the combined treatment experience with Pradaxa? has crossed one million patient-years(1) in the prevention of thromboembolic events in patients after surgery and in patients with non-valvular atrial fibrillation ...

Aquapharm Biodiscovery believes the marine-derived compound AQP-182 could help to tackle multi-drug resistant bacteria.

A new report from Thomson Reuters discusses the economic viability of developing drugs for rare diseases

India's contract research and manufacturing services sector is due to record 41.4 per cent growth.

PhRMA has delivered a robust defence of US pharmaceutical innovation in response to a recent article in the British Medical Journal.

An analytical article in the BMJ has dismissed claims of an innovation crisis in pharmaceutical R&D.

Nodality and Pfizer have announced a new collaborative effort to investigate potential compounds for autoimmune disease.

Novartis sees Africa as one of the next frontiers for clinical development.

AiCuris will present at the International Herpesvirus Workshop in Calgary, Canada, on its two front-running compounds targeting herpes viruses.

Covidien has opened a new $45 million R&D center in Shanghai, China. The center has two core focus areas: design of tailored products and discovery of breakthrough platforms in medical technology.

Tokyo-Tech and Astellas Pharma are teaming up to identify compounds with anti-protozoan activity.

ProMetic has granted NantPro BioSciences rights to its Plasma Protein Purification System and Prion Reduction technologies for the exclusive development and commercialisation of a plasma-derived biopharmaceutical product for the US market.

Takeda anticipates that these applications will be reviewed within the next six months. These NDAs were resubmitted in response to the complete response letter Takeda received from the FDA, dated April 25, 2012.

The company said the quadrivalent seasonal influenza virus-like particle vaccine triggered an immune response against all four strains of the bug after 21 days.

Global biopharmaceutical services provider Parexel has announced an alliance with the KDDF to accelerate global drug development.

The ODYSSEY program will enroll more than 22,000 patients. This includes over ten clinical trials evaluating the effect of SAR236553/REGN727 on the lowering of LDL-C and an 18,000 patient cardiovascular outcomes study.

Clinical trials conducted in developing regions appear to produce just as high-quality data as those performed in developed parts of the world.

A new low-dose treatment for acute pain following surgery has been shown to be effective in Phase 3 trials.

The trial did not meet its primary endpoint of extending the length of time that patients live without their disease getting worse.

The latest Research and Markets report highlights the significant changes that are taking place within pharmaceutical research and development.

The aim of Re-Liver is to reconstitute a standardized and reproducible bioartificial liver organoid (BLO) using healthy human liver as an architectural and biomaterial template.

Gentris and the Shanghai Institutes of Preventative Medicine will work together to accelerate healthcare innovations in the US and China.

Biopharmaceutical companies could significantly cut the cost of clinical trials by reducing the number of non-core procedures they perform.

A new report has highlighted the important role that the biotechnology sector is playing in global health research and development.

Polyphor will apply its MacroFinder drug discovery technology to identify and optimize macrocyclic drug candidates against targets selected by Boehringer.

The Pathway Modulator Technology works through the additional expression of an engineered enzyme in the producer cells.

Novartis has invested in the Explore programme to help fund cutting-edge pharmaceutical research in Quebec.

The results demonstrated positive trends in lung function as measured by FEV1 (forced expiratory volume in one second) and in the secondary outcome measure, rate of pulmonary exacerbations.